Psychosis in Parkinson's Disease

被引：1

作者：

Remz, Matthew ^{[1
]}

Salinas, Meagen ^{[1
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75390 USA

来源：

PSYCHIATRIC ANNALS | 2020年 / 50卷 / 03期

关键词：

DRUG-INDUCED PSYCHOSIS; VISUAL HALLUCINATIONS; RISPERIDONE TREATMENT; CLOZAPINE; SYMPTOMS; ZIPRASIDONE; OLANZAPINE; PHENOMENOLOGY; ARIPIPRAZOLE; RIVASTIGMINE;

D O I：

10.3928/00485713-20200210-02

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Clinically defined by consensus in 2007, Parkinson's disease psychosis (PDP) encompasses psychiatric symptoms of illusions, hallucinations, and delusions associated with Parkinson's disease. Since that time, an increase in research has yielded new insights into clinical features of PDP, how these symptoms evolve over time, and novel therapeutic targets. This article reviews the literature surrounding PDP, highlighting the spectrum of clinical manifestations, the pathophysiology, and treatment options. The article concludes with a treatment strategy incorporating the reviewed evidence.

引用

页码：112 / 119

页数：8

共 50 条

[21] Treatment of Psychosis and Dementia in Parkinson’s Disease [J].

Jennifer G. Goldman ;

Samantha Holden .

Current Treatment Options in Neurology, 2014, 16

[22] Pimavanserin as treatment for Parkinson's disease psychosis [J].

Fox, Susan H. .

LANCET, 2014, 383 (9916) :494-496

[23] Psychosis in Parkinson's disease: unexplained observations in a seemingly simple model [J].

Friedman, Joseph H. ;

Akbar, Umer .

EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (06) :595-596

[24] On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis [J].

Pagan, Fernando L. ;

Schulz, Paul E. ;

Torres-Yaghi, Yasar ;

Pontone, Gregory M. .

CNS DRUGS, 2024, 38 (05) :333-347

[25] Clinical and genetic analysis of psychosis in Parkinson's disease [J].

Radojevic, B. ;

Dragasevic, N. ;

Milovanovic, A. ;

Dobricic, V. ;

Svetel, M. ;

Petrovic, I. ;

Savic, M. ;

Jancic, I. ;

Stanisavljevic, D. ;

Marjanovic, A. ;

Brankovic, M. ;

Kostic, V. .

MOVEMENT DISORDERS, 2021, 36 :S319-S320

[26] Clozapine for the treatment of psychosis in Parkinson's disease: A review [J].

Auzou, P ;

Ozsancak, C ;

Hannequin, D ;

Moore, N ;

Augustin, P .

ACTA NEUROLOGICA SCANDINAVICA, 1996, 94 (05) :329-336

[27] Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis [J].

Bozymski, Kevin M. ;

Lowe, Denise K. ;

Pasternak, Kiersten M. ;

Gatesman, Travis L. ;

Crouse, Ericka L. .

ANNALS OF PHARMACOTHERAPY, 2017, 51 (06) :479-487

[28] Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial [J].

Cummings, Jeffrey ;

Isaacson, Stuart ;

Mills, Roger ;

Williams, Hilde ;

Chi-Burris, Kathy ;

Corbett, Anne ;

Dhall, Rohit ;

Ballard, Clive .

LANCET, 2014, 383 (9916) :533-540

[29] Psychosis, apathy, depression and anxiety in Parkinson's disease [J].

Gallagher, David A. ;

Schrag, Anette .

NEUROBIOLOGY OF DISEASE, 2012, 46 (03) :581-589

[30] Why psychosis is frequently associated with Parkinson's disease? [J].

Zhong, Jingmei ;

Wu, Shaoyuan ;

Zhao, Ying ;

Chen, Hui ;

Zhao, Naiwei ;

Zheng, Kunwen ;

Zhao, Zhong ;

Chen, Wenli ;

Wang, Bo ;

Wu, Kunhua .

NEURAL REGENERATION RESEARCH, 2013, 8 (27) :2548-2556

← 1 2 3 4 5 →